Ratings InBody Co.,Ltd

Equities

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
27,400 ^KRW	-2.84%		-3.01%	+8.09%

2023	InBody Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	InBody Releases BPBIO 220 and BPBIO 250	CI

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -99% by 2026.
The group's high margin levels account for strong profits.
Its low valuation, with P/E ratio at 9.13 and 7.81 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company has a low valuation given the cash flows generated by its activity.
Sales forecast by analysts have been recently revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

	1st Jan change	Capi.	ESG Refinitiv
INBODY CO.,LTD	+8.09%	262M	-
THERMO FISHER SCIENTIFIC	+12.81%	227B	B
DANAHER CORPORATION	+13.75%	192B	B-
INTUITIVE SURGICAL, INC.	+17.95%	136B	B-
BOSTON SCIENTIFIC CORPORATION	+28.25%	108B	A-
SIEMENS HEALTHINEERS AG	+1.67%	64.07B	A-
EDWARDS LIFESCIENCES CORPORATION	+17.90%	52.1B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B	B+
AGILENT TECHNOLOGIES, INC.	+10.52%	44.33B	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.93%	36.75B	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality